Affiliation:
1. Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran, Postal code: 14155-1339
Abstract
Abstract
An early diagnosis of bone metastases is very important for providing a profound decision on a subsequent therapy. In this study, a new
agent for SPECT-imaging of bone metastases,
111In-(4-{[(bis(phosphonomethyl))carbamoyl]methyl}-7,10-bis(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl) acetic acid
(111In-BPAMD) complex has been developed with specific activity of 2.85 TBq/mmol. Radiochemical purity of the
radiolabeled complex was checked by instant thin layer chromatography method indicated high radiochemical purity > 95% at
the optimal conditions. The complex demonstrated significant stability at room temperature and in human serum at least for
48 h. Hydroxyapatite (HA) binding assay showed high binding ability of the radiolabeled complex even at the low amounts of
HA. Also, log P measurements highlighted the strong hydrophilic nature of the complex. Biodistribution studies as well as planar
imaging after injection of the complex into the male Syrian mice showed major accumulation of the labelled compound in the bone
tissue. Totally, the obtained results indicated that 111In-BPAMD has interesting characteristics as an agent for
SPECT-imaging of the bone metastases.
Subject
Physical and Theoretical Chemistry
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献